

RSS: OB/GYN Grand Rounds 2025

Session Date: October 3, 2025 ● 8:00 AM – 9:00 AM

Title: OB/GYN Grand Rounds 2025 - 10/3/2025 - *Cystic Fibrosis: In Utero Exposure to Novel Therapies; Presented by Brian O'Sullivan, MD*

Session Speaker:

Ilana Cass, MD
VP Svc Ln & Dept Chair-Ob/Gyn
Dartmouth Hitchcock Medical Center

Brian P O'Sullivan, MD
Professor of Pediatrics
Dartmouth Health

Accreditation:

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Medical Association (AMA)

Dartmouth Health designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Learning Objectives:

At the conclusion of this learning activity, participants will be able to:

- 1 Discuss at least three examples of the current status of translation research in this clinical specialty.
- 2 1. Understand the basic defect of CF and its impact on reproduction
- 3 2. Recognize the potential role for highly effective modulator therapy on fetal outcomes
- 4 3. Be better able to counsel women with CF during pregnancy

Dartmouth Health adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies[^]. All relevant financial relationships have been mitigated prior to the commencement of the activity.

[^]*Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Tina C Foster, MD	Other Planning Committee Member	
Rebecca H Evans, MD	Other Planning Committee Member	
Ilana Cass, MD	Faculty	
Robert N Blatman, MD	Course Director	Nothing to disclose - 11/14/2024

Katelyn M. Danner	Activity Coordinator	Nothing to disclose - 10/15/2024
Brian P O'Sullivan, MD	Faculty	Nothing to disclose - 07/24/2025

Mobile Text-In Code for this Session Only

<Code>

Code Expires in 48 Hours

Text Requests for Credit to this Number:
(833-884-3375)

Need help?
clpd.support@hitchcock.org

Create New Account
dh.cloud-cme.com